Abstract 4913
Background
Patients with carcinoma prostate undergo rapid decline in bone health as measured by bone mineral density in the first 6 to 12 months of treatment with androgen deprivation. The WHO has developed the FRAX (Fracture Risk Assessment) Tool to predict long-term risk of major fractures and hip fracture. Guidelines are available for managing therapy related osteoporosis. This study is to characterize the risk (based on the FRAX tool) and management on the basis of guidelines in view of non-availability of bone matrix density assessments on basis of DEXA Scan.
Methods
A retrospective analysis of 196 consecutive patients receiving LHRH agonists at a single practice for the period of 2010 to 2018 was done. Data was collected after IRB clearance and included demographics, medical history, treatment history, history of ADT, bone health and its management. 10y fracture risk was calculated using the FRAX tool. Descriptive statistics were used for demographic analysis and to characterise the management of bone health. Paired t-Test was used to compare 10y fracture pre and post ADT.
Results
A total of 196 patients were seen. The mean age was 65.5y. 36% patients had Stage II disease and 56% had Stage III disease. All patients had PSA >10 and a Gleason Score >7 and Life expectancy <10y. 97% patients received LHRH agonists for a mean period of 13.8 + 18.1 months. 57% patients had >2 Risk for osteoporosis. Counselling for adverse effect of ADT and bone side effects was seen in 20% of patients. Bone health assessment was not available for 75% of patients. Bisphosphonate therapy was seen in 3% of patients. The risk of sustaining a major fracture increased from 26% to 34% (P < 0.001) on initiation of ADT. The risk of sustaining a hip fracture rose from 12% to 20%. Guidelines was followed for DEXA Scan, Calcium supplements and Vitamin D in 22%, 15%, and 8% respectively.
Conclusions
In addition to predisposing factors of osteoporosis, ADT increases risk of fracture in patients with ca prostate. There is room for improvement by increasing health literacy in multi-disciplinary team and Care providers. This is the first paper of its kind in developing countries including quality practice audit.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
G S Bhattacharyya.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5239 - Treatment patterns and outcomes for patients (pts) with anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer (NSCLC) in US clinical practice
Presenter: Matthew Krebs
Session: Poster Display session 1
Resources:
Abstract
5595 - Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
Presenter: Saadettin Kilickap
Session: Poster Display session 1
Resources:
Abstract
5840 - Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance
Presenter: Sebastian Michels
Session: Poster Display session 1
Resources:
Abstract
1905 - NTRK1-3 Genomic Fusions in Non-Small Cell Lung Cancer (NSCLC) Determined by Comprehensive Genomic Profiling
Presenter: Sai-Hong Ou
Session: Poster Display session 1
Resources:
Abstract
3016 - Preferential expression of the affected MET allele in lung carcinomas with heterozygous MET exon 14 skipping mutations: implications for clinical testing
Presenter: Evgeny Imyanitov
Session: Poster Display session 1
Resources:
Abstract
4120 - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew G Krebs
Session: Poster Display session 1
Resources:
Abstract
3764 - Patients with metastatic non-small cell lung cancer and targetable molecular alterations in Germany. Treatment and first outcome data from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Frank Griesinger
Session: Poster Display session 1
Resources:
Abstract
4070 - Crizotinib vs Platinum-based Chemotherapy as First-line Treatment for Advanced Non-small Cell Lung Cancer with Different ROS1 Fusion Variants
Presenter: Haiyan Xu
Session: Poster Display session 1
Resources:
Abstract
5528 - Genomic and clinical characterization of Non-small cell lung cancer (NSCLC) patients harboring mutations in FGFR2 and FGFR3
Presenter: Matthias Scheffler
Session: Poster Display session 1
Resources:
Abstract
3779 - The expression of HER2-gene polymorphisms -1985G>T and P1170A C>G and their association with the risk of development of lung adenocarcinoma
Presenter: Ivan Aleric
Session: Poster Display session 1
Resources:
Abstract